| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2018.09.059 |
| P698 | PubMed publication ID | 30297124 |
| P50 | author | Anna Wald | Q41122225 |
| Connie Celum | Q42571941 | ||
| Dalton Wamalwa | Q60557268 | ||
| Amalia S Magaret | Q87912727 | ||
| Jared M Baeten | Q89443633 | ||
| Kenneth Ngure | Q89958961 | ||
| Nelly Mugo | Q90832458 | ||
| Denise Galloway | Q91250425 | ||
| Lawrence Mwaniki | Q117266731 | ||
| P2093 | author name string | Anqi Cheng | |
| Linda Eckert | |||
| P2860 | cites work | Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement | Q28069669 |
| Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women | Q33182358 | ||
| Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 | Q33910699 | ||
| Incidence and progression of cervical lesions in women with HIV: a systematic global review | Q33924965 | ||
| The burden of human papillomavirus infections and related diseases in sub-saharan Africa | Q34089781 | ||
| Guidance on vaccination of HIV-infected children in Europe. | Q34251138 | ||
| Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. | Q34549645 | ||
| Long-term cumulative detection of human papillomavirus among HIV seropositive women | Q34899459 | ||
| Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children | Q35853410 | ||
| Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa | Q35887646 | ||
| Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children | Q36486823 | ||
| Human papillomavirus infection and disease in the HIV+ individual. | Q36900309 | ||
| Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals | Q36925235 | ||
| Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women | Q37084984 | ||
| Age-specific prevalence of human papillomavirus infection in males: a global review | Q37875961 | ||
| Immunising the HIV-infected child: a view from sub-Saharan Africa | Q38039620 | ||
| Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine | Q38380284 | ||
| Cervical cancer incidence after up to 20 years of observation among women with HIV. | Q38400222 | ||
| Associations between highly active antiretroviral therapy and the presence of HPV, premalignant and malignant cervical lesions in sub-Saharan Africa, a systematic review: current evidence and directions for future research | Q38646429 | ||
| Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay | Q40293794 | ||
| HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. | Q40613888 | ||
| Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. | Q40615908 | ||
| Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months | Q42248061 | ||
| Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial | Q42268011 | ||
| Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus | Q44547276 | ||
| Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women | Q45739196 | ||
| Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis | Q47225608 | ||
| Comprehensive control of human papillomavirus infections and related diseases. | Q51856187 | ||
| Conditional power calculations for clinical trials with historical controls. | Q51950789 | ||
| Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection | Q79922153 | ||
| P433 | issue | 46 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Kenya | Q114 |
| teenager | Q1492760 | ||
| HPV vaccine | Q900189 | ||
| P304 | page(s) | 7025-7032 | |
| P577 | publication date | 2018-10-05 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status | |
| P478 | volume | 36 |
| Q64083502 | A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women |
| Q94487420 | Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy |
| Q90290758 | Immunotherapy in People With HIV and Cancer |
Search more.